Key result
Annual medical costs among patients with alpha-1 antitrypsin deficiency were $127,537 for augmentation therapy users and $15,874 for non-users, with 75.3% of the cost difference attributable to the therapy.
Why the study?
Data estimating medical costs of patients with alpha-1 antitrypsin deficiency in the United States using a large claims database were lacking.
What are the direct medical costs associated with augmentation therapy use versus non-use in adult patients with alpha-1 antitrypsin deficiency?
Cohort (n=9,117)
What are the direct medical costs associated with augmentation therapy use versus non-use in adult patients with alpha-1 antitrypsin deficiency?
Absolute Event Rate: 127537% vs 15874%
p-value: p=<0.001
Augmentation therapy significantly increases the direct medical costs for patients with alpha-1 antitrypsin deficiency, primarily driven by the cost of the therapy itself.
Augmentation therapy markedly raises costs in alpha-1 antitrypsin deficiency; leaves open cost-effectiveness justification in real-world cohorts.
Background: This study is the first to utilize a large claims database to estimate medical costs of patients with alpha-1 antitrypsin deficiency (AATD) in the United States. Methods: Adult AATD patients were identified from the OptumLabs™ Data Warehouse. Insurer and patient out-of-pocket cost
No takes yet. Share an insight, caveat, or question.
Sieluk et al. (2018) conducted a cohort in Alpha-1 antitrypsin deficiency (AATD) (n=9,117). Augmentation therapy vs. Non-users was evaluated on Annual direct medical costs per person year (p=<0.001). Annual medical costs among patients with alpha-1 antitrypsin deficiency were $127,537 for augmentation therapy users and $15,874 for non-users, with 75.3% of the cost difference attributable to the therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: